According to Zacks, “Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company’s product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich. “
Separately, HC Wainwright restated a buy rating and set a $26.00 target price on shares of Ocuphire Pharma in a research report on Friday, March 25th.
Ocuphire Pharma (NASDAQ:OCUP – Get Rating) last announced its quarterly earnings data on Friday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). As a group, research analysts predict that Ocuphire Pharma will post -1.38 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the stock. Spire Wealth Management bought a new position in Ocuphire Pharma during the first quarter valued at $29,000. MCF Advisors LLC bought a new position in Ocuphire Pharma during the first quarter valued at $31,000. Morgan Stanley lifted its position in Ocuphire Pharma by 779.4% during the first quarter. Morgan Stanley now owns 6,156 shares of the company’s stock valued at $36,000 after purchasing an additional 5,456 shares during the last quarter. Squarepoint Ops LLC bought a new position in Ocuphire Pharma during the fourth quarter valued at $40,000. Finally, Powell Investment Advisors LLC bought a new position in Ocuphire Pharma during the first quarter valued at $44,000. Hedge funds and other institutional investors own 27.60% of the company’s stock.
Ocuphire Pharma Company Profile (Get Rating)
Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia.
- Get a free copy of the StockNews.com research report on Ocuphire Pharma (OCUP)
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.